ACE Stock Overview
Ascelia Pharma AB (publ), a biotech company, focuses on orphan oncology treatments in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Ascelia Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr12.34 |
| 52 Week High | kr17.98 |
| 52 Week Low | kr2.62 |
| Beta | 1.08 |
| 1 Month Change | 37.57% |
| 3 Month Change | 43.16% |
| 1 Year Change | -13.95% |
| 3 Year Change | -64.94% |
| 5 Year Change | -38.30% |
| Change since IPO | -50.39% |
Recent News & Updates
Recent updates
Is Ascelia Pharma (STO:ACE) In A Good Position To Invest In Growth?
May 11
Ascelia Pharma (STO:ACE) Is In A Good Position To Deliver On Growth Plans
Aug 05We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth
Jan 24We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth
Aug 23Companies Like Ascelia Pharma (STO:ACE) Are In A Position To Invest In Growth
May 19Here's What Ascelia Pharma AB (publ)'s (STO:ACE) Shareholder Ownership Structure Looks Like
Mar 07Helena Wennerström Is The Independent Director of Ascelia Pharma AB (publ) (STO:ACE) And They Just Picked Up 125% More Shares
Dec 09We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth
Nov 26Shareholder Returns
| ACE | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 16.4% | 0.5% | 1.1% |
| 1Y | -13.9% | -3.8% | 10.2% |
Return vs Industry: ACE underperformed the Swedish Biotechs industry which returned -1.8% over the past year.
Return vs Market: ACE underperformed the Swedish Market which returned 11.1% over the past year.
Price Volatility
| ACE volatility | |
|---|---|
| ACE Average Weekly Movement | 15.6% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in SE Market | 13.3% |
| 10% least volatile stocks in SE Market | 3.6% |
Stable Share Price: ACE's share price has been volatile over the past 3 months.
Volatility Over Time: ACE's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 13 | Magnus Corfitzen | www.ascelia.com |
Ascelia Pharma AB (publ), a biotech company, focuses on orphan oncology treatments in Sweden. It has two drug candidates in clinical development, which include Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, which is in Phase 2 trial for the treatment of gastric cancer. The company was incorporated in 1999 and is headquartered in Malmö, Sweden.
Ascelia Pharma AB (publ) Fundamentals Summary
| ACE fundamental statistics | |
|---|---|
| Market cap | kr416.57m |
| Earnings (TTM) | -kr109.29m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.8x
P/E RatioIs ACE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACE income statement (TTM) | |
|---|---|
| Revenue | kr0 |
| Cost of Revenue | kr0 |
| Gross Profit | kr0 |
| Other Expenses | kr109.29m |
| Earnings | -kr109.29m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 16, 2024
| Earnings per share (EPS) | -3.24 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ACE perform over the long term?
See historical performance and comparison